September 11, 2023, the U.S. Food and Drug Administration approved reformulated monovalent COVID shots by Pfizer and Moderna for use in individuals 12 years of age and older. They also issued emergency use authorization (EUA) for use of the reformulated jabs in children aged 6 months to 11 years
October 3, 2023, the FDA issued EUA for an updated non-mRNA COVID vaccine, Nuvaxovid, a subunit protein vaccine made by Novavax. The spike protein is produced inside moth cells. According to health authorities, this may encourage vaccine uptake among those who are “hesitant about the mRNA vaccines”
The updated COVID shots correspond to the Omicron variant XBB.1.5., which was the dominant variant in the U.S. for most of 2023, but which has since been replaced by other variants
High-risk individuals who were recommended to get additional doses will have received as many as six mRNA injections at this point — a three-dose primary series in 2021, two boosters to the primary series during 2021/2022, and one bivalent booster in the fall of 2022. The latest reformulation for XBB.1.5 will be the seventh
Americans are tired of the endless boosters and have come to recognize both their ineffectiveness and dangers. Only 2% of the population has opted to receive the latest shot, and a recent study found the most commonly reported reason for not having been boosted was a prior SARS-CoV-2 infection, followed by concern about vaccine side effects, or that it would not protect from against infection

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.